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Cancer of the kidney accounts for approximately 3.5% of all malignancies and is the third most common cancer of 
the urinary tract.1 With the increased frequency 
and sophistication of radiological imaging, the rate 
of incidental findings of renal cortical tumours 
has steadily increased. The greatest incidence of 
asymptomatic small renal masses occurs in elderly 
patients with multiple comorbidities.2 Incidentally 
discovered small renal masses are being diagnosed 
with greater frequency3 and they now account for 
48% to 66% of renal cell carcinoma (RCC) diagnosis.4 
The incidence of renal cell carcinoma (RCC) at 
autopsy has been reported to be approximately 
2%.5 The incidence of RCC has been increasing in 
all age groups, with the greatest increase occurring 
in patients with localised tumours, suggesting a 
migration toward earlier stages as a result of earlier 
detection.6 
Considering the improved prognosis of incidental 
RCC, the difficulty in diagnosing benign tumours 
preoperatively, the excellent results associated 
with partial nephrectomy, and the possibility 
that these lesions themselves may have a less 
aggressive biology, it becomes apparent that not 
all solid renal masses are optimally treated by 
radical nephrectomy.7 Consequently, changes in 
the approach to the management of these masses 
have occurred. Traditionally, renal parenchymal-
sparing procedures were reserved for patients 
with a functional or an anatomic impairment of 
the contralateral kidney. Currently, appropriately 
located lesions 4 cm or less in size are treated, 
with excellent long-term survival, by nephron-
sparing surgery even in patients with a normal 
contralateral kidney.8  The aim of this paper is to 
review the literature about incidental renal tumours 
in adults. A literature search was performed using 
the PubMed database and selecting papers from 
1950 to the present using the term ‘incidental renal 
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إكتشاف األورام الصغرية يف الكلى بالصدفة عند الكبار
حممد �شامل املرهون
لذلك ينبغي  الأطباء،  الكثري من  التي تواجه  الطبية  الكبار من امل�شاكل  الكلى بال�شدفة عند  ال�شغرية يف  الأورام  اإكت�شاف  اأ�شبح  امللخ�ص: 
التعامل معها بعد معرفة طبيعتها وكيفية عالجها. هدف هذه املقالة هو مراجعة ما ن�رش عن هذه الأورام و طرق عالجها. اإن معظم اأورام الكلى 
ال�شغرية )اأقل من 4 �شم( عند الكبار املكت�شفة عن طريق ال�شدفة هي اأورام حميدة . اإن  اأف�شل طرق عالجها ا�شتئ�شال الورم اجلزئي باملنظار 
اجلراحي اأو الفتح عند املر�شي �شغار ال�شن القادرين علي حتمل العملية. من طرق العالج الأخرى لهذه الأورام عند كبار ال�شن غري القادرين 
على حتمل العملية اجلراحية عالج الإبر املجمدة مع اأخذ عينة من الكلىاأو للمالحظة الطبية بدون تدخل جراحي. 
ة. مفتاح الكلمات: م�شادفة، اأورام، كلوي، �رَشَطاَنُة اخَلاَليا الُكْلِويَّ
abstract: Incidental renal tumours are becoming an important clinical problem that many physicians will need 
to deal with. A good knowledge of the nature of these tumours and how to manage them is therefore needed. The 
aim of this paper is to review the literature about incidental renal tumours in adults. Many incidentally discovered 
small renal tumours (<4 cm) are benign and of low stage, grade and progression potential. The preferred 
management in young fit patients is open or laparoscopic nephron-sparing surgery. Treatment alternatives 
include needle-ablative therapies and surveillance in elderly unfit patients. Tumour renal biopsy is encouraged 
prior to needle-ablative therapy and surveillance. Awareness about incidental renal masses and their management 
is essential for treating doctors. 
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The differential diagnosis of an incidentally detected 
renal mass includes both benign and malignant 
processes. Malignant renal masses include RCC, 
sarcoma, lymphoma, metastatic disease (especially 
lung, breast, prostate, colon, testes), and urothelial-
based tumours of the pelvis and collecting system. 
Of these, RCCs account for most such masses. 
Lesions classified as benign include simple cysts, 
oncocytoma, adenoma, angiomyolipoma, fibroma, 
and lipoma, [Table 1].8
Tumour Growth Rate 
Studies on the natural history of small renal 
tumours have shown that their growth was, in 
general, slow or undetectable. Approximately one-
quarter to one-third of small renal tumours did 
not show radiographic growth, and the overall 
mean growth rate has been reported to be 0.28 cm 
per year (range: 0.09–0.86).4,9 A meta-analysis by 
Chawla et al. found that, over a mean follow-up of 
34 months, a majority of 234 untreated renal lesions 
had a slow growth rate (approximately 0.28 cm per 
year), and metastases were rare (1%).9 Kouba et 
al.2 published the results of a retrospective study 
including 43 patients with 46 renal masses (24% of 
tumours >4 cm) who underwent active surveillance 
of enhancing solid or cystic, Bosniak IV (i.e. thick 
wall, thick septations, course calcifications, density 
more than 20, enhancement) renal masses. A subset 
of 13 patients who ultimately underwent surgical 
intervention was also examined. The mean delay to 
intervention was 12 months. At a mean follow-up 
of 36 months, renal masses grew in 74% of patients 
with a mean (median) growth rate of 0.70 (0.35) 
cm per year, no patient died of RCC, and none had 
evidence of metastatic disease. Initial tumour size 
(3.1 versus 2.6 cm, P = 0.450) was similar in the 
intervention and non-intervention group, and the 
growth rate did not correlate with initial tumour 
size. The authors suggested that active surveillance 
for renal masses is an appropriate option for 
selected patients, especially those with competing 
comorbidities. Delayed intervention after an initial 
period of surveillance did not appear to impact 
pathological outcomes adversely.
In a large retrospective study by Frank et al.,10 2,935 
solid renal tumours were treated in a 30-year period. 
Of these tumours, 12.8% were benign and 87.2% 
were malignant. Of the tumours <1 cm in diameter, 
46.3% were benign while 98% of malignant tumours 
were low grade. Of 250 tumours <2 cm in diameter, 
30% were benign and only 9.2% were high grade 
malignancies. As the tumour size increases, there is 
a significantly greater probability that the tumour is 
malignant versus benign, clear cell versus papillary 
RCC, and high-grade versus low-grade RCC.
Initial tumour size is not a predictor of the 
subsequent growth rate. In the study conducted 
by Kouba et al.,2 tumours with an initial size > 4 
cm had growth rates similar to those of smaller 
tumours. The majority of small renal masses grow 
and the majority is cancerous. One cannot safely 
assume that a lack of growth on serial computed 
tomography (CT) scan confirms the absence of 
malignancy. No clinical or radiological predictors of 
growth rate have been identified.11 Tumour growth 
rate determination alone probably will not give 
clinicians enough information to predict accurately 
the behaviour of all small renal masses. Cytogenetic, 
immunohistochemical, or other investigations done 
on needle biopsies and the study of new radiologic 
parameters using computed tomography (CT) 
scanning and magnetic resonance imaging (MRI) 
may be helpful in identifying patients who have renal 
tumours with good prognostic factors and a long 
natural history and who therefore may primarily be 
followed conservatively.12   
Role of Renal Biopsy 
The use of renal mass biopsy to guide treatment 
decisions is still controversial. The current indications 
for renal mass biopsy are: a) to differentiate benign 
from malignant small renal tumours;13 b) the use of 
molecular markers obtained from tumour biopsies 
for separating indolent from aggressive tumours;14 
c) prior to or during ablative therapies and during 
follow up after ablative therapies, especially 
radiofrequency ablation, for defining treatment 
success or failure,15 and d) to rule out non-renal cell 
primary tumours (metastasis and lymphoma) or 
benign conditions (abscess), which may not require 
surgery. Biopsy has also been used to confirm the 
diagnosis and the histological subtype of renal 
primary lesion in patients with disseminated 
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Literature Overview 
Renal cell carcinoma, which represents 2% of all 
adult cancers, is the most lethal of common urologic 
cancers, with approximately 35% of patients dying 
from the disease at the 5-year mark.20 The incidence 
of RCC has risen steadily each year during the 
last three decades  in most of the world, with an 
average increase of 2% to 3% per year.21  Tobacco 
use and obesity are the most consistently identified 
risk factors for RCC, accounting for  about 20% and 
30% of cases, respectively.20 Other risk factors for 
RCC include hypertension and a family history of 
the disease. 
Incidental detection of clinical stage 1 (<7.0 cm), 
solid, enhancing renal masses accounts for more 
than 50% of RCC cases, and these tumours are 
more likely to be organ confined and associated 
with an improved prognosis.22 The biology of these 
tumours is heterogeneous, and there are multiple 
management options available, ranging from 
observation to radical nephrectomy. Approximately 
20% of clinical stage T1 renal masses are benign, 
and only 20% to 30% of malignant tumours in 
this size range demonstrate potentially aggressive 
features, with substantial variance based on patient 
age, gender and tumour size.23 The differential 
diagnosis of a renal mass includes: RCC, renal 
adenoma, oncocytoma, angiomyolipoma, urothelial 
carcinoma, metastatic tumour, abscess, infarct, 
vascular malformation or pseudotumour. With the 
exception of fat-containing angiomyolipoma, no 
current scanning methods can distinguish between 
benign and malignant solid tumours or between 
indolent and aggressive tumour biology. Tumours 
less than 3 cm may be more likely to be benign24 
and the aggressive potential of RCC increases 
dramatically beyond this size.25
In recent years, the potential role of biopsy for 
localised renal tumours has been revisited, in 
part driven by the recognition that 20% clinical 
stage T1 renal masses may represent benign 
disease and could be considered for less aggressive 
management.25 In addition, the accuracy and safety 
of renal mass biopsy has improved substantially 
due to further refinements in CT- and MRI-
guided techniques. A review of studies since 2001, 
demonstrates that the false-negative rate with renal 
mass biopsy is now only 1%, and the incidence of 
symptomatic complications is relatively low, with 
metastases or unresectable retroperitoneal 
masses.16 Urothelial carcinoma carries a higher risk 
of seeding than RCC and a percutaneous biopsy in 
the presence of radiological suspicion of renal pelvic 
tumour or positive urinary cytology should only be 
performed after careful consideration of the risks 
and benefits.16 
The high proportion of benign lesions (19% to 26%)17 
in tumours ≤ 4cm justifies preoperative histological 
diagnosis to decrease the rate of unnecessary renal 
surgery which has been reported to be 34%.18 The 
safety and accuracy of renal core biopsy has been 
questioned, in particular its accuracy for small 
lesions.19 In incidental renal masses of <5 cm, it 
has been reported that renal core biopsy had 100% 
accuracy for distinguishing benign from malignant 
lesions and 98% accuracy for determining 
histological tumour type,18 indicating that this 
technique can be used successfully for small 
lesions, including those that are asymptomatic 
and detected incidentally. However, there are 
limitations and complications with renal core 
biopsy of small lesions. The limitation is the 
considerable proportion of biopsy specimens that 
have insufficient tissue for analysis or contain only 
necrotic tissue, normal tissue or blood. This is 
referred to as the nondiagnostic rate or failure rate 
which has been reported to range from 0% to 22%.18 
This high failure rate in small tumours is partly due 
to more difficult visualisation and targeting, and the 
biopsy needle displacing small masses rather than 
penetrating them.16 The potential complications 
of renal core biopsy include tumour seeding along 
the needle track, bleeding, arteriovenous fistula, 
infection and pneumothorax.16 
 
Table 1:  Differential diagnosis of renal masses in adults
Cysts Tumours Inflammatory lesions
Simple Malignant masses
   Renal cell carcinoma
   Lymphoma
   Sarcomas





   Renal adenomas
   Angiomyolipomas 
   Oncocytomas 
   Others
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only a very small percentage (<2 %) requiring 
any form of intervention.26 Needle-tract seeding 
also appears to be exceedingly rare, assuming 
appropriate patient selection. While another 10-
15% of renal mass biopsies are indeterminate, 
this is much less concerning than a false negative, 
which would lead to observation of a malignancy. 
Given the significant heterogeneity in the biological 
aggressiveness of clinical stage T1 renal masses and 
the wide range of treatment options now available, 
renal mass biopsy is now being used increasingly 
for patient counselling and clinical decision making. 
This approach is appropriate for patients in whom 
a wide range of management options are under 
consideration, ranging from surgery to observation. 
Renal mass biopsy is not indicated, however, for 
healthy patients who are unwilling to accept the 
uncertainty associated with this procedure or for 
older patients who will only consider conservative 
management options regardless of biopsy results. 
Incorporation of molecular analysis has shown great 
promise to further improve accuracy of renal mass 
biopsy/aspiration and remains a research priority.16 
The most prominent molecular markers are the vhl 
gene, altered expression of carbonic anhydrase IX 
(CAIX) or the B7H1 molecule, cell cycle regulators 
such as p27, cyclin D1, pRb and p53 and markers of 
cellular proliferation such as Ki-67. 
Histopathological evaluation of surgically managed 
suspicious renal masses in published reports indicate 
that the frequency of benign pathologic findings is 
higher for tumours less than 4 cm in size compared 
to tumours more than 4 cm. This information is 
important for physicians when counselling patients 
on treatment options. For tumours 4 cm or less in 
size, the percentage of benign masses reported were 
20% (18 of 90),27 19.8% (23 of 116),28 and  23% (65 of 
280).29 For tumours > 4 cm, the percentage of benign 
masses reported was 8% (8 of 96).27 The data by 
Luciani et al.,22 in a study of 1,092 patients, confirm 
a rapid and dramatic change in the epidemiologic 
and clinical characteristics of renal cancer, with an 
increasing number of incidentally found tumours: 
13% in 1982 compared to 59.2% in 1997. The 
incidentally discovered tumours presented with 
a lower stage (74.3% versus 49.1%), grade (75.5% 
versus 56.9%), and percentage of metastases at 
presentation (10.4% versus 19.6%) compared to 
the symptomatic neoplasms. In a large study of 
482 patients evaluating the histologic type of renal 
tumours according to size, Schachter et al.17 found 
smaller lesions (≤4 cm) that proved to be malignant 
were less likely to be of clear-cell histology (50% 
versus 72.8%) and more likely to be papillary (15.8% 
versus 9.4%) than were larger (>4 cm) lesions. 
Given the differences in the biological behaviour of 
the various histological subtypes of these tumours, 
these data are important in patient counselling 
about the treated and untreated natural history 
of small renal masses. The impact of histological 
subtype on prognosis is important.30 Amin and 
colleagues found that chromophobe and papillary 
subtypes have the best prognosis and conventional 
clear-cell RCCs had a worse prognosis as judged by 
Renal mass detected incidentally on CT scan or
ultrasound examination
Does the patient have symptoms?
Renal CT and
urologic referral
What is the Bosniak 
classification of the mass?








Renal CT surveillance at
6 to12 month intervals
Renal CT, possible renal
MRI before referral for
surgical exploration
Renal CT, possible renal
MRI before referral for
surgical excision
Figure 1:  Management of incidental renal mass in adults
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for patients with a normal contralateral kidney or 
partial nephrectomy as a recommended modality 
when there is a need to preserve renal function. 
However, active surveillance should be discussed 
with patients who want to avoid surgery or who 
are considered high risk for surgical therapy; and 
thermal ablation may be discussed as treatment 
option which is less effective due to an increased 
risk of local recurrence.  
Conclusion 
With the increased frequency and sophistication of 
radiological imaging, the rate of incidental findings 
of renal cortical tumours has steadily increased. 
Awareness about incidental renal masses and their 
management is essential as they are becoming an 
important clinical problem that many physicians 
will face. The main issue is whether to be aggressive 
or conservative with small renal masses, knowing 
that a significant number of these small tumours 
are benign and most of them grew slowly.  In recent 
years, the potential role of biopsy for localised 
renal tumours has been revisited, in part driven 
by the recognition that 20% clinical stage T1 renal 
masses may represent benign disease and could 
be considered for less aggressive management. 
In addition, the accuracy and safety of renal mass 
biopsy has improved substantially due to further 
refinements in CT- and MRI-guided techniques. 
Incorporation of molecular analysis has shown 
great promise to improve further the accuracy of 
renal mass biopsy/aspiration and remains a research 
priority. Currently, small renal masses 4 cm or less 
are treated, with excellent long-term survival, by 
nephron-sparing surgery even in patients with a 
normal contralateral kidney. 
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